NL-OMON48852已完成不适用
Myeloid cell reprogramming in the context of radioiodine therapy in patients with non-medullary thyroid carcinoma - Myeloid cell reprogramming in thyroid carcinoma
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •-newly diagnosed patients with TC that are therapy naïve and are planned to
- •receive conventional treatment by surgery followed by RAI.
- •-no evidence of local or distant metastases
- •-patients with TC with evidence of distant metastases (either newly diagnosed
- •patients who are therapy naïve or patients with persistent or recurrent
- •disease) and are planned to receive conventional treatment by surgery followed
- •-at least 4 months since the previous treatment with RAI (in the patients who
- •have had this treatment in the past)
- •-patients with MNG in which the decision has been taken to undergo surgery
- •because of obstructive symptoms or for cosmetic reasons
- •-patients with MNG in which the decision has been taken to undergo RAI because
- •of obstructive symptoms.
- •-healthy individuals without evidence of thyroid disease.
排除标准
- •Excluded from participation in this study will be subjects who are/have:
- •Mentally incompetent;
- •Pregnant or breastfeeding;
- •Known inflammatory or infectious diseases or an immunosuppressive status;
- •Using medication interfering with the immune system;
- •Reduced platelets counts or other conditions associated with an increased risk
- •of bleeding.
- •Severe comorbidities: other active malignancy (except for basal cell
- •carcinoma), serious psychiatric pathology;
- •A self-reported alcohol consumption of >21 units per week.
研究者
相似试验
Unknown
不适用
Myeloid cell reprogramming in thyroid carcinomaThyroid carcinomaNL-OMON21311Radboudumc50
尚未招募
不适用
Investigation of the T cell metabolic reprogramming during immunotherapy in oncologic patientsC43Malignant melanoma of skinDRKS00023625niversitätsklinikum Freiburg50
已完成
不适用
Epigenetic reprogramming of monocytes in patients with coronary atherosclerosis1001108210003216atherosclerosisNL-OMON38690niversitair Medisch Centrum Sint Radboud40
进行中（未招募）
1 期
START-NET: A randomized clinical trial to compare personalized vs non-personalized radionuclide therapy with 177Lu-DOTATOCPatients with SSTR+, advanced, progressive NET Grade 1-3 of any origin for whom Peptide-receptor radionuclide therapy, PRRT, is considered the mostappropriate treatment option in relation to other approved or available investigational agents for the specific tumor subtype.MedDRA version: 21.0Level: LLTClassification code 10062476Term: Neuroendocrine tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-002218-15-SERegion Skåne300
尚未招募
3 期
GUM THICKNESS MODIFICATION TRIACTRI/2022/12/048131MINISTRY OF DEFENCE